EXINI Diagnostics AB

Our Vision
We aim to empower patients for better healthcare with Artificial Intelligence.
AI in Healthcare is Our Passion
We develop advanced medical devices powered with Artificial Intelligence.
Solutions to Real Problems
We employ Artificial Intelligence for objective and clinically relevant analysis of medical images.
From Lund to New York
We are partnered with a global leader in theranostic medicine to target and treat cancer.

News!

EXINI’s Artificial Intelligence enabled product received FDA clearance on GE Healthcare’s XELERIS platform
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the use of EXINI’s artificial intelligence enabled automated bone scan index (aBSI) on GE Healthcare’s Xeleris platform. EXINI has entered into a global software licensing agreement with GE Healthcare for the rights to EXINI bone, a vendor neutral stand-alone variant of aBSI that is enabled with artificial intelligence. Under the terms of the non-exclusive agreement EXINI will receive tiered licensing fees per license sold.
Read More
Lantheus Completes Merger
with Progenics
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that it has completed its previously announced merger with Progenics Pharmaceuticals, Inc. (“Progenics”) (Nasdaq: PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer. The merger agreement was first announced on October 2, 2019.
Read More
Previous
Next

aBSI

Read about our automatic bone scan index software.

Join Our Team

Find our open positions and send us your application.

Find Us at the Top of Lund

Get in contact with us.

EXINI

Find out more about EXINI and what we do.

What do the experts say about the future of AI in medical imaging?

Providing a quantifiable and reproducible assessment of PSMA uptake and distribution in the body is critical here to enable precision oncology in prostate cancer.
Andrew J. Armstrong, MD.
Divisions of Medical Urology and Oncology, Duke University, NC, USA
The quantification and standardization of PSMA scan reports is a major step forward to enhance the reproducibility and timeliness of scan interpretations.
Matthew B. Rettig, MD.
Professor of medicine and urology, David Geffen School of Medicine at UCLA, CA, USA
Modern chess AI running on even modest hardware can easily defeat the greatest human grand masters. There’s no reason to think the eventual outcome will be any different with diagnostic imaging. PSMA-AI is a step towards that goal.
Stephan Probst
Chief of Nuclear Medicine, Jewish General Hospital, MontrÉal, Canada.
Artificial intelligence is essential to advance molecular imaging in cancer, to capture the power of MI for detection and quantitating molecular expression of individual tumor lesions within the prostate cancer patient.
Steven M. Larson, MD.
Department of Radiology, Memorial Sloan Kettering Cancer Center, NY, USA